Detalles de la búsqueda
1.
Prehospital treatment with zalunfiban (RUC-4) in patients with ST- elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the CELEBRATE trial.
Am Heart J
; 258: 119-128, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36592878
2.
Prepercutaneous coronary intervention Zalunfiban dose-response relationship to target vessel blood flow at initial angiogram in st-elevation myocardial infarction - A post hoc analysis of the cel-02 phase IIa study.
Am Heart J
; 262: 75-82, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37088164
3.
Antiplatelet strategy during ad-hoc percutaneous coronary intervention in elective patients: how aggressive should we be?
Neth Heart J
; 31(11): 424-425, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37861974
4.
Complementary Pharmacotherapy for STEMI Undergoing Primary PCI: An Evidence-Based Clinical Approach.
Am J Cardiovasc Drugs
; 22(5): 463-474, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35316483
5.
Current and Future Insights for Optimizing Antithrombotic Therapy to Reduce the Burden of Cardiovascular Ischemic Events in Patients with Acute Coronary Syndrome.
J Clin Med
; 11(19)2022 Sep 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-36233469
6.
Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: the Dutch Cangrelor registry.
Eur Heart J Open
; 1(3): oeab028, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35923807
Resultados
1 -
6
de 6
1
Próxima >
>>